Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eli Lilly's China R&D Head Tony Zhang On Looking At The Universe Of Possibilities In China: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly was the first to coin the term FIPNET, which brings the focus of becoming a fully integrated pharmaceutical network on partnerships rather than doing it all as a fully integrated pharmaceutical company, or FIPCO. Eli Lilly's Head of China R&D Tony Zhang sat down with PharmAsia News along the sidelines of the recent Shanghai R&D Summit to discuss Lilly's approach to R&D in China. Much of doing R&D in China is about building up a local ecosystem for innovation and, according to Zhang, it is about being a "sower and a grower," rather than just a "seeker and a picker."

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts